Standard Nuclear, Inc. (STDN) is an Oak Ridge, Tennessee-based advanced nuclear fuel company that designs and manufactures TRISO fuel — coated-particle fuel designed for small modular reactors, microreactors, and government and space programs. It is the only independent U.S. producer with industrial-scale TRISO manufacturing capability and listed on the NYSE in July 2026 at $15.00 per share.
On Friday morning, the stock was trading at $8.54, down $0.47 or 5.22%, from the prior session's close of $9.01. The direction is unambiguously negative. No new company announcement, regulatory filing or analyst action was identified for Friday's session; the move is a continuation of the de-rating that began when third-quarter results were published on Nov. 12 and has now erased roughly 46% of the share price in six sessions.
The Nov. 12 report was operationally solid and financially unsettling. Revenue rose to $6.0 million from $0.9 million a year earlier, ahead of the roughly $5.5 million consensus, and the loss of $0.10 per share was narrower than expected. The company also completed delivery of Radiant's Kaleidos reactor core — the first full commercial TRISO core supplied by an independent U.S. manufacturer — and total contract backlog more than doubled to $577.2 million.
What broke the stock was the margin trajectory. GAAP gross margin collapsed to 30% from 67% in the second quarter as cost of revenue climbed to $4.2 million during completion of the Radiant core. Management explicitly walked back prior commentary that strong margins were durable, stating that neither the second- nor third-quarter figure reflects run-rate economics. General and administrative costs jumped to $15.5 million, including $9.5 million of share-based compensation, pushing the net loss to $13.1 million from $3.4 million sequentially. Even excluding stock compensation, the adjusted operating loss nearly doubled year over year to $4.8 million.
Investors have treated that margin reset as a valuation event rather than a one-quarter timing issue, and each subsequent session has extended the markdown.
The second leg of the selloff is about time. Authorization to operate the Tennessee and Idaho facilities was pushed from a fourth-quarter 2026 target to February 2027, pending an operational readiness review. That defers the second-quarter goal of 2.5 metric tons of annual installed throughput and leaves module capacity at just 0.5 metric tons per year as of Sept. 30, with the SN-0 plant running at about 25% of that capacity.
The backlog figure also drew scrutiny. Of the $577.2 million total, $443.5 million consists of purchase options exercisable at customer discretion; funded backlog, the firmer measure, is $119.6 million. Qualified pipeline, meanwhile, fell to $844.7 million from $986.3 million. For a company valued near $1.4 billion on roughly $6 million of quarterly revenue, the gap between announced and committed demand matters, and the market is repricing accordingly.
Volume has been running well above the sub-300,000-share pace typical through October, with recent sessions trading between roughly 370,000 and 800,000 shares — a signal that institutional repositioning, not retail noise, is driving the tape. Friday's activity was lighter in the early going.
The move has been company-specific. No peer or sector-wide catalyst was identified to explain the decline, and the selling has persisted across sessions in which the broader market was mixed, which points to stock-level reassessment rather than a macro rotation. Technically, the shares have broken below every meaningful short- and medium-term reference level, including the $11 and $10 handles, and are now testing the $8.79 area that marked Thursday's low. A decisive break there would put the July low of $7.05 back in play; the September high of $17.34 now sits more than 100% above the current price.
The score runs from 0 — no meaningful news and a move in line with the stock's normal behavior — to 100, meaning transformative news paired with a rare, extreme price move. This event scores 33 out of 100.
The verified news was material: a revenue beat undercut by a 37-point sequential gross-margin decline and a multi-month delay to the authorization that unlocks volume production. That is significant relative to a company of this size, though it is now six sessions old rather than fresh. The price move itself was unremarkable by this stock's standards. The typical daily absolute move across the last 89 sessions is about 4.9%, so Friday's 5.2% decline is only roughly 1.1 times normal, and 30 of those sessions produced equal or larger moves. A moderate catalyst combined with an ordinary swing for this name produces a below-midpoint score.
The near-term calendar is dominated by the Department of Energy operational readiness review and the February 2027 authorization target for the Tennessee and Idaho facilities. Any further slippage would extend the period in which revenue depends on lumpy, delivery-specific product shipments from the SN-0 pilot line. Fourth-quarter and full-year 2026 results, expected in the first quarter of 2027, will be the first real test of whether gross margin recovers toward the adjusted 40% level management cites as more representative.
On the commercial side, investors will watch conversion of purchase options into firm orders from Radiant and Antares, progress at the Framatome joint venture in Richland, Washington — where NRC-licensed production is targeted for 2027 — and whether the surplus plutonium program negotiation becomes a signed contract. Analyst coverage is uniformly constructive, with a consensus rating of Strong Buy established after a wave of post-IPO initiations, so the risk is less about sentiment and more about execution against a lengthening timeline. The principal uncertainties are authorization timing, margin durability as volume scales, and continued cash consumption, which stood at $223.1 million at quarter-end.
Tickeron’s Trending AI Robots page offers a curated view of automated trading strategies, drawn from a library of hundreds of AI bots covering thousands of tickers. Only the strongest performers under current market conditions make the featured list. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the page helps investors compare approaches side by side rather than relying on a single model. Reviewing the current leaders is a practical next step for anyone building a systematic process around volatile names like this one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ChemicalsSpecialty